Monica M. Bertagnolli, MD, is the Richard E. Wilson Professor of Surgery in the
Field of Surgical Oncology at Harvard Medical School, and Chief of the Division of Surgical
Oncology at Dana Farber/Brigham and Women’s Cancer Center (DF/BWCC). She is also a member of the
Gastrointestinal Cancer and Sarcoma Disease Centers at DF/BWCC, where she collaborates with
colleagues in medical oncology, radiation oncology, and pathology to treat cancer patients in a
tertiary care setting.
Dr. Bertagnolli graduated from Princeton University, and attended medical school at the University
of Utah. She trained in surgery at Brigham and Women’s Hospital, and was a research fellow at the
Dana Farber Cancer Institute. Dr. Bertagnolli’s laboratory work focuses upon understanding the role
of the inflammatory response in epithelial tumor formation. From 1994-2011, she led
gastrointestinal correlative science initiatives within the NCI-funded Cancer Cooperative Groups,
where she facilitated integration of tumor-specific molecular markers of treatment outcome into
nation-wide clinical cancer treatment protocols.
Dr. Bertagnolli has had numerous leadership roles in multi-institutional cancer clinical research
consortia, and currently serves as the Group Chair of the Alliance for Clinical Trials in Oncology,
a new NCI-funded clinical trials group formed in 2011 by merger of Cancer and Leukemia Group B, the
North Central Cancer Treatment Group, and the American College of Surgeons Oncology Group. She is
also the Chief Executive Officer of Alliance Foundation Trials, LLC, a not-for-profit corporation
that conducts international cancer clinical trials. In 2016, Dr. Bertagnolli was elected to serve
as President of the American Society of Clinical Oncology, a term that will begin in June, 2018.